United Therapeutics Corporation announced today that, based on its most recent interactions with the U.S. FDA, the FDA's pending regulatory review of the New Drug Application (NDA) for Tyvaso(TM) (inhaled treprostinil) will likely extend beyond its originally anticipated April 30, 2009, action date.
the details can be read here.
No comments:
Post a Comment